CNS Pharmaceuticals (CNSP) files for 9.79M share offering by selling stockholders May 19, 2026 05:00PM
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress May 14, 2026 08:00AM
CNS Pharmaceuticals raises $22.5 million in private placement May 4, 2026 07:09AM
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing May 4, 2026 07:00AM
CNS Pharmaceuticals shifts strategy to neurology and oncology pipeline Mar 11, 2026 08:35AM
View Older Stories

Mar 11, 2026 08:35AM CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
Mar 2, 2026 08:25AM CNS Pharmaceuticals names Lynne Kelley as chief medical officer
Mar 2, 2026 08:25AM CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
Feb 17, 2026 08:27AM CNS Pharmaceuticals names three executives to new leadership team
Feb 17, 2026 08:25AM CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation
Jan 27, 2026 09:04AM CNS Pharmaceuticals names Rami Levin as new CEO
Jan 27, 2026 09:00AM CNS Pharmaceuticals Issues Letter to Shareholders
Dec 17, 2025 07:00AM CNS Pharmaceuticals names Rami Levin as new president and CEO
Dec 17, 2025 07:00AM CNS Pharmaceuticals Announces CEO Transition
Nov 17, 2025 08:35AM CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 10, 2025 08:45AM CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
Sep 12, 2025 07:48AM Maxim Group Upgrades CNS Pharmasceuticals Inc. (CNSP) to Buy
Sep 3, 2025 09:15AM CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 15, 2025 08:05AM CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 14, 2025 09:15AM CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Jul 22, 2025 08:45AM CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
Jul 22, 2025 08:40AM JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
Jul 18, 2025 08:00AM CNS Pharmaceuticals announces 1-for-12 reverse stock split
Jul 18, 2025 08:00AM CNS Pharmaceuticals Announces Reverse Stock Split
Jul 9, 2025 09:32AM CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment
Jun 24, 2025 09:15AM CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287
Jun 5, 2025 08:05AM CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
May 16, 2025 08:05AM CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025 09:42AM CNS Pharmaceuticals (CNSP) Prices 3.95M Share Offering at $1.265/sh
May 13, 2025 09:35AM CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
May 13, 2025 07:04AM CNS Pharmaceuticals (CNSP) Acquires Orphan Drug Designation for TPI 287
May 13, 2025 07:00AM CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
Apr 1, 2025 08:05AM CNS Pharmaceuticals Reports Full Year 2024 Financial Results
Mar 25, 2025 08:02AM CNS Pharmaceuticals (CNSP) Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Mar 25, 2025 08:00AM CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Mar 25, 2025 07:55AM CNS Pharmaceuticals (CNSP) Halted, News Pending
Feb 26, 2025 09:07AM CNS Pharmaceuticals (CNSP) Provides Update on Current Cash Position and NASDAQ Listing
Feb 26, 2025 09:05AM CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
Feb 20, 2025 09:00AM CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
Feb 19, 2025 09:00AM CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Feb 19, 2025 08:36AM CNS Pharmaceuticals (CNSP) announces 1-for-50 reverse stock split
Feb 19, 2025 08:30AM CNS Pharmaceuticals Announces Reverse Stock Split
Feb 18, 2025 09:00AM CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
Feb 10, 2025 08:00AM CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
Dec 5, 2024 09:10AM CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Nov 25, 2024 09:02AM CNS Pharmaceuticals (CNSP) Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine
Nov 25, 2024 09:00AM CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line
Nov 18, 2024 09:00AM CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
Nov 15, 2024 09:10AM CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
Nov 4, 2024 09:15AM CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Nov 1, 2024 09:03AM CNS Pharmaceuticals (CNSP) Granted Exception to Regain Nasdaq Compliance
Nov 1, 2024 09:00AM CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Oct 23, 2024 02:51PM CNS Pharmaceuticals (CNSP) Announces Pricing of $3 Million Registered Direct Offering of Common Stock
Oct 23, 2024 02:50PM CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Oct 10, 2024 09:00AM CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
View Older Stories